Shantou Institute of Ultrasonic Instrument
301602
Hubei Sinophorus Electronic Materials
688545
Pansoft
300996
4
Jiayu Holding
300117
5
Wuxi Taclink Optoelectronics Technology
688205
US Stock MarketDetailed Quotes
KNSA Kiniksa Pharmaceuticals International
- 18.755
- +0.045+0.24%
Trading Jan 22 12:36 ET
1.35BMarket Cap-156.29P/E (TTM)
18.835High18.480Low90.74KVolume18.780Open18.710Pre Close1.69MTurnover0.40%Turnover Ratio93.78P/E (Static)72.20MShares28.15052wk High3.10P/B425.64MFloat Cap16.56052wk Low--Dividend TTM22.69MShs Float32.880Historical High--Div YieldTTM1.90%Amplitude5.010Historical Low18.652Avg Price1Lot Size
About Kiniksa Pharmaceuticals International Company
Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.
Company Profile
SymbolKNSA
Company NameKiniksa Pharmaceuticals International
Listing DateMay 24, 2018
Issue Price18.00
Founded2024
CEOMr. Sanj K. Patel
MarketNASDAQ
Employees297
Fiscal Year Ends12-31
Address23 Old Bond Street,3rd Floor
CityLondon
ProvinceGreater London
CountryUnited Kingdom of Great Britain and Northern Ireland (the)
Zip CodeW1S 4PZ
Phone44-781-431-9100
Websitehttps://www.kiniksa.com
Company Executives
- Name
- Position
- Salary
- Sanj K. Patel
- Chief Executive Officer and Chairman of the Board
- 5.30M
- Michael R. Megna
- Chief Accounting Officer and Group Vice President, Finance
- --
- Mark Ragosa
- Senior Vice President and Chief Financial Officer
- --
- Ross Moat
- Senior Vice President and Chief Commercial Officer
- --
- John F. Paolini, M.D.,PhD
- Senior Vice President and Chief Medical Officer
- 1.79M
- Eben Tessari
- Senior Vice President and Chief Operating Officer
- 1.75M
- Cantey Boyd
- Director
- --
- Dr. Felix J. Baker,PhD
- Lead Independent Director
- 411.06K
- Tracey L. McCain, Esq.
- Independent Director
- 365.36K
- Kimberly J. Popovits
- Independent Director
- 362.66K
- Thomas R. Malley
- Independent Director
- 380.36K
- G. Bradley Cole
- Independent Director
- 365.36K
- Dr. Stephen R. Biggar,M.D.,PhD
- Independent Director
- 371.96K
- Dr. Richard S. Levy,M.D.
- Independent Director
- 459.75K
- Dr. Barry D. Quart,Pharm.D.
- Independent Director
- 372.55K
Trending Stocks
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Stocks & Industries to Watch Under Trump's Second Presidency
Key takeaways Tech stocks underwent substantial growth due to tax cuts and reduced corporate regulations in Trump's first term along with defense and aerospace
Discussing
December CPI comes in as expected, is that enough?
U.S. December CPI rose 2.9% year-on-year, aligning with expectations but marking a three-month inflation increase trend. The market reacted
In One Chart
Jan 15 22:05
Here's the Breakdown for December CPI, in One Chart